|
?:authorAffiliation
|
-
[\'Quality Use of Medicines and Pharmacy Research Centre, Clinical and Health Sciences, University of South Australia, Adelaide, South Australia, Australia.\', \'Vaccine Medical, Scientific and Clinical Affairs, Pfizer Inc., New York, New York, USA.\', \'Vaccines Clinical Research & Development, GlaxoSmithKline, Wavre, Belgium.\', \'Office of Preventive Medicine, Taiwan Centers for Disease Control, Taipei, Taiwan.\', \'School of Pharmacy, Sungkyunkwan University, Suwon, South Korea.\', \'School of Pharmacy, Institute of Clinical Pharmacy and Pharmaceutical Sciences, College of Medicine, National Cheng Kung University, Tainan, Taiwan.\', \'Research Department of Practice and Policy, UCL School of Pharmacy, London, UK.\', \'Centre for Safe Medication Practice and Research, Department of Pharmacology and Pharmacy, The University of Hong Kong, Hong Kong.\', \'Department of Health Convergence, Ewha Womans University, Seoul, South Korea.\', \'Epidemiology and Benefit Risk, Sanofi Pasteur Ltd., Toronto, Ontario, Canada.\', \'Astellas Pharma Inc., Northbrook, Illinois, USA.\', \'Global Medical Epidemiology, Worldwide Medical and Safety, Pfizer Inc., New York, New York, United States of America.\', \'Faculty of Pharmaceutical Sciences, Ubon Ratchathani University, Ubon Ratchathani, Thailand.\', \'Global Healthcare Consulting, New Delhi, India.\', \'Department of Global Health, University of Washington, Seattle, Washington, USA.\', \'Brighton Collaboration, The Task Force for Global Health, Decatur, Georgia, USA.\']
|
![[This page as RDF]](https://research.tib.eu/covid-19/static/rdf-icon.gif){kind=icon}